Menu Search
Equities

Bayer AG

BAYX.N:GER

Bayer AG

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)19.52
  • Today's Change-0.026 / -0.13%
  • Shares traded5.66m
  • 1 Year change-42.57%
  • Beta1.0783
Data delayed at least 15 minutes, as of Nov 21 2024 16:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 18-Nov-24
Select bar for recommendation details.
Recommendations18-Nov-24
Buy1
Outperform3
Hold18
Sell1
Strong Sell0

Share price forecast in EUR

The 22 analysts offering 12 month price targets for Bayer AG have a median target of 27.50, with a high estimate of 40.00 and a low estimate of 22.00. The median estimate represents a 40.71% increase from the last price of 19.54.
High104.7%40.00
Med40.7%27.50
Low12.6%22.00

Dividends in EUR

In 2023, Bayer AG reported a dividend of 0.11 EUR, which represents a 95.42% decrease from last year. The 18 analysts covering the company expect dividends of 0.11 EUR for the upcoming fiscal year, a decrease of 0.91%.
Div growth (TTM)-95.42%
More ▼

Earnings history & estimates in EUR

On Nov 12, 2024, Bayer AG reported 3rd quarter 2024 earnings of 0.24 per share.
The next earnings announcement is expected on Mar 05, 2025.
Average growth rate+74.53%
Bayer AG reported annual 2023 earnings of 6.39 per share on Mar 05, 2024.
Average growth rate+1.04%
More ▼

Revenue history & estimates in EUR

Bayer Aktiengesellschaft had 3rd quarter 2024 revenues of 9.97bn. This missed the 10.12bn consensus estimate of the 8 analysts following the company. This was 30.72% below the prior year's 3rd quarter results.
Average growth rate+0.29%
Bayer Aktiengesellschaft had revenues for the full year 2023 of 47.64bn. This was 6.11% below the prior year's results.
Average growth rate+2.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.